CD8A and neoplasm: The results from the first trial revealed that intravenous infusion of enadenotucirev in patients with epithelial tumors can induce infiltration of a large number of CD8+ T cells into most tumor samples [63] and provided a rationale to investigate the virus in combination with an anti-PD-1 Ab, nivolumab, in patients with epithelial carcinoma (NCT02636036).